Close

pCDCAR1 HIV1 h(BBζ) (CAR-MZ218)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-HIV-1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target HIV-1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HIV-1 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of HIV-1 infection.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • HIV-1
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • HIV-1 infection
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 3BNC117
  • Host
  • Human
  • Target Species
  • Virus
  • Gene Name
  • Human immunodeficiency virus 1
  • Synonyms
  • HIV-1, Human immunodeficiency virus 1

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 CAR-T cells displayed preferable immunophenotype.

CAR Construction : 3BNC117-41BB-CD3ζ Latest CAR Construction

Fig.1 CAR-T cells displayed preferable immunophenotype.

The subset composition of UTD/3B/3BD CAR-T cells were measured by surface expression of CD45RA and CD62L.

Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., ... & Zhu, H. (2021). HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo. Frontiers in Microbiology, 12.

Complete CAR data FCM

Fig.2 CAR-T cells displayed preferable proliferation.

CAR Construction : 3BNC117-41BB-CD3ζ Latest CAR Construction

Fig.2 CAR-T cells displayed preferable proliferation.

CAR-T cells sorted for CAR expression were incubated with LHL2/3 cells (5 × 105cells) at 1:1 ratio for 5 days, and CAR+cells were counted daily to evaluate thein vitro proliferation.

Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., ... & Zhu, H. (2021). HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo. Frontiers in Microbiology, 12.

Complete CAR data FuncS

Fig.3 Cell killing assay.

CAR Construction : 3BNC117-41BB-CD3ζ Latest CAR Construction

Fig.3 Cell killing assay.

Direct killing of LEL6 was performed using the LDH release assay.

Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., ... & Zhu, H. (2021). HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo. Frontiers in Microbiology, 12.

Complete CAR data Cyt

Fig.4 cytotoxicity assay.

CAR Construction : 3BNC117-41BB-CD3ζ Latest CAR Construction

Fig.4 cytotoxicity assay.

Direct cytotoxicity effects on Jurkat cells, as the Env negative control here, were detected

Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., ... & Zhu, H. (2021). HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo. Frontiers in Microbiology, 12.

Complete CAR data ELISA

Fig.5 TNF-α, IL-2 and IFN-γ production in co-cultures.

CAR Construction : 3BNC117-41BB-CD3ζ Latest CAR Construction

Fig.5 TNF-α, IL-2 and IFN-γ production in co-cultures.

Anti-HIV CAR-T cells were co-cultured with LEL6 cells (1 × 10^4cells) at 10:1 for 24 h, and supernatants were collected for ELISA.

Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., ... & Zhu, H. (2021). HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo. Frontiers in Microbiology, 12.

Complete CAR data BI

Fig.6 CAR-T cells eliminated LEL6 cells in vivo.

CAR Construction : 3BNC117-41BB-CD3ζ Latest CAR Construction

Fig.6 CAR-T cells eliminated LEL6 cells in vivo.

CAR-T cells displayed superior anti-HIV function in an HIV NCG mouse model.

Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., ... & Zhu, H. (2021). HIV-1-specific CAR-T cells with cell-intrinsic PD-1 checkpoint blockade enhance anti-HIV efficacy in vivo. Frontiers in Microbiology, 12.

CAR scFv data SPR

Fig.7 Surface plasmon resonance analyses.

CAR Construction : Latest CAR Construction

Fig.7 Surface plasmon resonance analyses.

SPR sensorgrams showing the bindingof bNAbs expressed as IgG1 (green), IgA1 (blue), and IgA2 (red) to YU-2 gp140 or gp120 ligands expressed as normalized response units (RU) over time.

Lorin, V., Malbec, M., Eden, C., Bruel, T., Porrot, F., Seaman, M. S., ... & Mouquet, H. (2017). Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity. Mucosal Immunology, 10(3), 814-826.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-HIV-1 (3BNC117) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-MZ218). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.